People Jack Schalken

Profile

prof. dr. Jack Schalken



About Jack Schalken

Discovery and clinical validation of new biomarkers for GU cancers (diagnostic, prognostic, predictive and therapy follow up). My team focuses on hypothesis driven approaches combined with ‘agnostic’ approaches, particularly whole genome sequencing, whole transcriptome profiling and -sequencing. This has also led to the discovery and validation of new molecular based risk calculator for PrCa (commercialized as SelectMDx) and the identification and exploration of actionable/drugable targets for GU cancers, particularly the androgen receptor and epithelial to mesenchymal transition. These two lines of research merge into an integral effort to develop models and tools for the individualized treatment of cancer. To that end preclinical models are developed, including, but not limited to 2D cell culture -, 3D (‘organoid type’ ),- 3D spheroid - and animal models.

Jack Schalken is inventor on over 20 patents and co-founder of  Noviogendix (acquired by MDxHealth in 2015) and Oncodrone.

Positions

  • full professor exp. Urologie

Education / Agenda

  • 1971-1977 Secondary school (Cobbenhagen College, Atheneum beta, Tilburg)
  • 1977-1984 University (Chemistry, Catholic University Nijmegen)
  • 1987 PhD (Catholic University Nijmegen). Promoters: Prof. H.P.J. Bloemers and Prof. F.M.J. Debruyne. Title of thesis: Gene expression in human malignancies.

Personal prizes & awards

  • 2015: Dominique Chopin Award Life time achievement award by the European Association for Urology (ESUR section)
  • 2012: Movember award- GAP1 (40 K for research)

Additional Functions

  • Board Member European Urology Scholarship program.
  • Member of the editorial board of various SCI scientific journals, including European Urology: the highest quoted urology 'specialty journal' (index, 10,476).
  • Co-founder of the biotechnological spin-off company NovioGendix (2006, with Dr. Willem Melchers and ir. Rob Tweehuysen). NovioGendix won the Mercator Award 2009.
read more

Additional Functions

  • Board Member European Urology Scholarship program.
  • Member of the editorial board of various SCI scientific journals, including European Urology: the highest quoted urology 'specialty journal' (index, 10,476).
  • Co-founder of the biotechnological spin-off company NovioGendix (2006, with Dr. Willem Melchers and ir. Rob Tweehuysen). NovioGendix won the Mercator Award 2009.
  • Co-founder of Oncodrone (RUNME spin-off, 2013).

Social media